Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marc Steven Sabatine, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. UH3TR000901 (DAS, SAUMYA) Aug 1, 2013 - Jul 31, 2018
    NIH/NCATS
    Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
    Role: Co-Principal Investigator
  2. UH2TR000901 (DAS, SAUMYA) Aug 1, 2013 - Jul 31, 2015
    NIH/NCATS
    Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
    Role: Co-Principal Investigator
  3. R01HL098280 (GERSZTEN, ROBERT E) Mar 15, 2010 - Jan 31, 2015
    NIH/NHLBI
    Metabolomic Biomarkers of Early Myocardial Injury
    Role: Co-Principal Investigator
  4. RC1HL099634 (SABATINE, MARC S) Sep 30, 2009 - Aug 31, 2012
    NIH/NHLBI
    Genetic Risk Stratification to Identify Individuals for Early Statin Therapy
    Role: Principal Investigator
  5. RC1HL099692 (SABATINE, MARC S) Sep 30, 2009 - Aug 31, 2011
    NIH/NHLBI
    Biomarkers of Prognosis and Response to Therapy in Acute Coronary Syndromes
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Ophuis TO, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. Efficacy and Safety with Ticagrelor in Patients with Prior Myocardial Infarction in the Approved European label: Insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019 Jun 20. PMID: 31218354.
    Citations:    
  2. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019 Jun 18; 73(23):2961-2970. PMID: 31196453.
    Citations:    
  3. Sabatine MS, Giugliano RP, Leiter LA. Correctly understanding the diabetes data in FOURIER. Diabetes Obes Metab. 2019 Jun 10. PMID: 31183961.
    Citations:    
  4. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Jun 10. PMID: 31196815.
    Citations:    
  5. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 Jun 10. PMID: 31202949.
    Citations:    
  6. Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019 May 22. PMID: 31116355.
    Citations:    
  7. Wiviott SD, Raz I, Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2019 05 09; 380(19):1881-1882. PMID: 31067395.
    Citations:    
  8. Zelniker TA, Jarolim P, Scirica BM, Braunwald E, Park JG, Das S, Sabatine MS, Morrow DA. Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes. J Am Heart Assoc. 2019 May 07; 8(9):e011444. PMID: 31020897.
    Citations:    
  9. Qamar A, Giugliano RP, Sabatine MS. Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. JAMA Cardiol. 2019 May 01. PMID: 31042267.
    Citations:    
  10. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 Apr 23; 139(17):2022-2031.